BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine ...
Amneal Pharmaceuticals has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector designed for patients to self-administer for acute migraine and cluster headaches ...
The latest version of Instron’s Autoinjector Testing System was developed in close collaboration with CDMOs and pharmaceutical device manufacturers. It can perform thorough functioning testing on ...
Brekiya ® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results